← Leaderboards
William Borkowsky
New York University School Of Medicine
$9,487,417
Attributed
$9,487,417
Total exposure
61
Grants
31
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–10$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$9,487,417 · 61
By mechanism
U01$2,344,348 · 1
M01$2,288,691 · 52
P30$1,661,389 · 3
R01$1,498,897 · 2
T32$1,101,049 · 1
P01$505,359 · 1
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Victor J Torres$18,227,816
- Henry J Pollack$169,000
- George Miller$7,866,873
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectPediatric AidsHuman Therapy EvaluationChild (0-11)Hiv InfectionsAids TherapyCombination ChemotherapyAntiaids AgentClinical Trial Phase IDrug Screening /EvaluationPharmacokineticsAdolescence (12-20)Human Immunodeficiency Virus 1Pathologic ProcessResearch PersonnelFundingComputer Retrieval Of Information On Scientific Projects DatabaseSourceUnited States National Institutes Of HealthGrantInstitutionResourcesPolymerase Chain Reaction
Grant awards (118)
Virology Core$127,698
P30 · FY2010 · AI · contact PI
VIROLOGY CORE$306,877
P30 · FY2009 · AI · contact PI
VIROLOGY CORE$323,161
P30 · FY2008 · AI · contact PI
CLINICAL TRIAL: PACTG 1025: PERINATAL CORE PROTOCOL (AIDS)$207,013
M01 · FY2008 · RR · contact PI
Core--HIV Virology and Sequencing$190,876
P01 · FY2008 · AI · contact PI
CLINICAL TRIAL: IMPAACT P1065: QUADRIVALENT MENINGOCOCCAL CONJUGATE VACCINE IN Y$117,833
M01 · FY2008 · RR · contact PI
MONITORING ART TOXICITIES IN HIV-UNINFECTED CHILDREN BORN TO HIV-INFECTED WOMEN$92,361
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFEC$73,253
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PACTG P1047: QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE IN HIV-IN$15,927
M01 · FY2008 · RR · contact PI
PACTG P1055: PSYCHIATRIC CO-MORBIDITY IN PERINATALLY HIV-INFECTED CHILDREN$15,927
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PACTG 390: ANTIRETROVIRAL REGIMENS AND TREATMENT-SWITCHING STRAT$12,736
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ACTG 219: PEDIATRIC LATE OUTCOMES (AIDS)$6,373
M01 · FY2008 · RR · contact PI
VIROLOGY CORE$254,951
P30 · FY2007 · AI · contact PI
PACTG 1025: PERINATAL CORE PROTOCOL (AIDS)$245,832
M01 · FY2007 · RR · contact PI
ACTG 219: PEDIATRIC LATE OUTCOMES (AIDS)$239,247
M01 · FY2007 · RR · contact PI
Core--HIV Virology and Sequencing$89,450
P01 · FY2007 · AI · contact PI
PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFECTED CHILDREN$79,018
M01 · FY2007 · RR · contact PI
PACTG 1006: EFFECTS OF HAART ON THE RECOVERY OF IMMUNE FUNCTION IN HIV+ CHILDREN$37,316
M01 · FY2007 · RR · contact PI
PACTG 390: ANTIRETROVIRAL REGIMENS AND TREATMENT-SWITCHING STRATEGIES (AIDS)$10,977
M01 · FY2007 · RR · contact PI
PACTG P1038: LOPINAVIR/RITONAVIR IN PEDIATRIC SUBJECTS WITH HIV PREVIOUSLY TREAT$10,977
M01 · FY2007 · RR · contact PI
PACTG P1061S: IMMUNOLOGIC MEMORY AFTER VACCINATION IN HAART-TREATED CHILDREN$6,585
M01 · FY2007 · RR · contact PI
VIROLOGY CORE$244,559
P30 · FY2006 · AI · contact PI
PACTG 1025: PERINATAL CORE PROTOCOL (AIDS)$142,091
M01 · FY2006 · RR · contact PI
ACTG 219: PEDIATRIC LATE OUTCOMES (AIDS)$122,031
M01 · FY2006 · RR · contact PI
Core--HIV Virology and Sequencing$91,323
P01 · FY2006 · AI · contact PI
PACTG 1006: EFFECTS OF HAART ON THE RECOVERY OF IMMUNE FUNCTION IN HIV+ CHILDREN$63,526
M01 · FY2006 · RR · contact PI
PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFECTED CHILDREN$26,745
M01 · FY2006 · RR · contact PI
PACTG P1038: LOPINAVIR/RITONAVIR IN PEDIATRIC SUBJECTS WITH HIV PREVIOUSLY TREAT$13,375
M01 · FY2006 · RR · contact PI
PACTG 1015: INTERRUPTING HAART IN HIV+ CHILDREN W/ LOW VIRAL LOADS$10,030
M01 · FY2006 · RR · contact PI
PACTG 394: TENOFOVIR DF IN HIV-1 INFECTED PREGNANT WOMEN AND THEIR INFANTS$8,360
M01 · FY2006 · RR · contact PI
PACTG 382: DMP 266 & NELFINAVIR COMBINATION IN HIV-INFECTED CHILDREN (AIDS)$5,015
M01 · FY2006 · RR · contact PI
PERSISTENCE OF IMMUNE RESPONSE TO VACCINIA IN IMMUNOCOMPETENT AND HIV+ ADULTS$5,015
M01 · FY2006 · RR · contact PI
ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN HIV-INFECTED CHILDREN$3,345
M01 · FY2006 · RR · contact PI
PACTG P1055: PSYCHIATRIC CO-MORBIDITY IN PERINATALLY HIV-INFECTED CHILDREN$3,345
M01 · FY2006 · RR · contact PI
PACTG 390: ANTIRETROVIRAL REGIMENS AND TREATMENT-SWITCHING STRATEGIES (AIDS)$1,670
M01 · FY2006 · RR · contact PI
PACTG P1045: PREVALENCE OF ABNORMALITIES IN VERTICALLY HIV-INFECTED CHILDREN$1,670
M01 · FY2006 · RR · contact PI
VIROLOGY CORE$233,068
P30 · FY2005 · AI
Core--HIV Virology and Sequencing$88,555
P01 · FY2005 · AI
PERSISTENCE OF IMMUNE RESPONSE TO VACCINIA IN IMMUNOCOMPETENT AND HIV+ ADULTS$79,896
M01 · FY2005 · RR
ACTG 219: PEDIATRIC LATE OUTCOMES$60,567
M01 · FY2005 · RR
PACTG 1025: PERINATAL CORE PROTOCOL$59,275
M01 · FY2005 · RR
PACTG 1006: EFFECTS OF HAART ON THE RECOVERY OF IMMUNE FUNCTION IN HIV+ CHILDREN$28,348
M01 · FY2005 · RR
PACTG P1045: PREVALENCE OF ABNORMALITIES IN VERTICALLY HIV-INFECTED CHILDREN$28,348
M01 · FY2005 · RR
PACTG 1015: INTERRUPTING HAART IN HIV+ CHILDREN W/ LOW VIRAL LOADS$25,774
M01 · FY2005 · RR
ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN HIV-INFECTED CHILDREN$20,617
M01 · FY2005 · RR
PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFECTED CHILDREN$5,153
M01 · FY2005 · RR
PACTG 390: ANTIRETROVIRAL REGIMENS AND TREATMENT-SWITCHING STRATEGIES$3,866
M01 · FY2005 · RR
PACTG 1013: RITONAVIR &INDINAVIR IN HIV+ CHILDREN FAILING OTHER HIV THERAPY$2,579
M01 · FY2005 · RR
PACTG 382: DMP 266 &NELFINAVIR COMBINATION IN HIV-INFECTED CHILDREN$2,579
M01 · FY2005 · RR
NIAID AIDS INSTITUTIONAL TRAINING GRANT$189,142
T32 · FY2004 · AI
ACTG 219: Pediatric Late Outcomes$69,665
M01 · FY2004 · RR
Core--HIV Virology and Sequencing$45,155
P01 · FY2004 · AI
PACTG 1025: PERINATAL CORE PROTOCOL$33,250
M01 · FY2004 · RR
PACTG1015: Interrupting HAART in HIV+ Children w/ Low Viral Loads$21,375
M01 · FY2004 · RR
PACTG 1020-A: NOVEL PROTEASE INHIBITOR (BMS-232632) IN HIV-INFECTED CHILDREN$19,000
M01 · FY2004 · RR
PERSISTENCE OF IMMUNE RESPONSE TO VACCINIA IN IMMUNOCOMPETENT AND HIV+ ADULTS$18,209
M01 · FY2004 · RR
PACTG 1006: Effects of HAART on the Recovery of Immune Function in HIV+ Children$11,084
M01 · FY2004 · RR
PACTG 345: Ritonavir Therapy in HIV-1 Infected Infants and Children$11,084
M01 · FY2004 · RR
PACTG 1013: Ritonavir &Indinavir in HIV+ Children Failing Other HIV Therapy$7,125
M01 · FY2004 · RR
PACTG 382: DMP 266 &Nelfinavir Combination in HIV-Infected Children$6,334
M01 · FY2004 · RR
ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN HIV-INFECTED CHILDREN$4,750
M01 · FY2004 · RR
PACTG1024: Pneumococcal Vaccine + Routine Vaccination in HIV+ Children on HAART$3,166
M01 · FY2004 · RR
NIAID AIDS INSTITUTIONAL TRAINING GRANT$187,114
T32 · FY2003 · AI
PEDIATRIC AIDS CLINICAL TRIALS UNIT$311,023
U01 · FY2002 · AI
NIAID AIDS INSTITUTIONAL TRAINING GRANT$181,113
T32 · FY2002 · AI
NOVEL ANIVIRAL THERAPY IN STABLE EXPERIENCED HIV-1 INFECTED CHILDREN$0
M01 · FY2002 · RR
ACTG 265--SAFETY &IMMUNOGENICITY OF VARICELLA VACCINE IN HIV INFECTED CHILDREN$0
M01 · FY2002 · RR
ACTG 230--RECOMBINANT HIV 1 ENVELOPE ANTIGEN IN CHILDREN BORN TO HIV+ MOTHERS$0
M01 · FY2002 · RR
GANCICLOVIR IN HIV INFECTED CHILDREN WITH ASYMPTOMATIC CMV AND LOW CD4 COUNT$0
M01 · FY2002 · RR
CORE--VIROLOGY FACILITY$0
P30 · FY2002 · AI
ACTG 366: RAD 1 FOUR DRUG ANTIRETROVIRAL COMBINATIONS BASED ON PRIOR$0
M01 · FY2002 · RR
PROAB3004: SAFETY, EFFICACY &PK 0F 141W94 + CURRENT RX IN HIV+ CHILDREN$0
M01 · FY2002 · RR
BIOLOGY OF PEDIATRIC HEPATITIS C INFECTION$0
M01 · FY2002 · RR
PATHOGENESIS OF HIV INFECTION$0
M01 · FY2002 · RR
PEDIATRIC LATE OUTCOMES$0
M01 · FY2002 · RR
PEDIATRIC AIDS CLINICAL TRIALS UNIT$1,025,528
U01 · FY2001 · AI
BIOLOGY OF PEDIATRIC HEPATITIS C INFECTION$481,619
R01 · FY2001 · DA
NIAID AIDS INSTITUTIONAL TRAINING GRANT$279,957
T32 · FY2001 · AI
CORE--VIROLOGY FACILITY$171,075
P30 · FY2001 · AI
ABI PRISM 7700 SEQUENCE DETECTION SYSTEM$87,684
S10 · FY2001 · RR
CORE--VIROLOGY FACILITY$0
P30 · FY2001 · AI
ACTG 366: RAD 1 FOUR DRUG ANTIRETROVIRAL COMBINATIONS BASED ON PRIOR$0
M01 · FY2001 · RR
PROAB3004: SAFETY, EFFICACY &PK 0F 141W94 + CURRENT RX IN HIV+ CHILDREN$0
M01 · FY2001 · RR
BIOLOGY OF PEDIATRIC HEPATITIS C INFECTION$0
M01 · FY2001 · RR
PATHOGENESIS OF HIV INFECTION$0
M01 · FY2001 · RR
PEDIATRIC LATE OUTCOMES$0
M01 · FY2001 · RR
NOVEL ANIVIRAL THERAPY IN STABLE EXPERIENCED HIV-1 INFECTED CHILDREN$0
M01 · FY2001 · RR
ACTG 265--SAFETY &IMMUNOGENICITY OF VARICELLA VACCINE IN HIV INFECTED CHILDREN$0
M01 · FY2001 · RR
ACTG 230--RECOMBINANT HIV 1 ENVELOPE ANTIGEN IN CHILDREN BORN TO HIV+ MOTHERS$0
M01 · FY2001 · RR
GANCICLOVIR IN HIV INFECTED CHILDREN WITH ASYMPTOMATIC CMV AND LOW CD4 COUNT$0
M01 · FY2001 · RR
PEDIATRIC AIDS CLINICAL TRIALS UNIT$1,007,797
U01 · FY2000 · AI
PATHOGENESIS OF PEDIATRIC HIV INFECTION$548,068
R01 · FY2000 · HD
BIOLOGY OF PEDIATRIC HEPATITIS C INFECTION$469,210
R01 · FY2000 · DA
NIAID AIDS INSTITUTIONAL TRAINING GRANT$263,723
T32 · FY2000 · AI
ACTG 230--RECOMBINANT HIV 1 ENVELOPE ANTIGEN IN CHILDREN BORN TO HIV+ MOTHERS$21,006
M01 · FY2000 · RR
ACTG 366: RAD 1 FOUR DRUG ANTIRETROVIRAL COMBINATIONS BASED ON PRIOR$21,006
M01 · FY2000 · RR
PROAB3004: SAFETY, EFFICACY &PK 0F 141W94 + CURRENT RX IN HIV+ CHILDREN$21,006
M01 · FY2000 · RR
BIOLOGY OF PEDIATRIC HEPATITIS C INFECTION$21,006
M01 · FY2000 · RR
PATHOGENESIS OF HIV INFECTION$21,006
M01 · FY2000 · RR
PEDIATRIC LATE OUTCOMES$21,006
M01 · FY2000 · RR
NOVEL ANIVIRAL THERAPY IN STABLE EXPERIENCED HIV-1 INFECTED CHILDREN$21,006
M01 · FY2000 · RR
ACTG 265--SAFETY &IMMUNOGENICITY OF VARICELLA VACCINE IN HIV INFECTED CHILDREN$21,006
M01 · FY2000 · RR
GANCICLOVIR IN HIV INFECTED CHILDREN WITH ASYMPTOMATIC CMV AND LOW CD4 COUNT$21,006
M01 · FY2000 · RR
PROAB3004: SAFETY, EFFICACY &PK 0F 141W94 + CURRENT RX IN HIV+ CHILDREN$0
M01 · FY2000 · RR
ACTG 265--SAFETY &IMMUNOGENICITY OF VARICELLA VACCINE IN HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
BIOLOGY OF PEDIATRIC HEPATITIS C INFECTION$0
M01 · FY2000 · RR
ACTG 230--RECOMBINANT HIV 1 ENVELOPE ANTIGEN IN CHILDREN BORN TO HIV+ MOTHERS$0
M01 · FY2000 · RR
NOVEL ANIVIRAL THERAPY IN STABLE EXPERIENCED HIV-1 INFECTED CHILDREN$0
M01 · FY2000 · RR
PATHOGENESIS OF HIV INFECTION$0
M01 · FY2000 · RR
GANCICLOVIR IN HIV INFECTED CHILDREN WITH ASYMPTOMATIC CMV AND LOW CD4 COUNT$0
M01 · FY2000 · RR
TWO SAQUINAVIR TREATMENT REGIMENS IN HIV CHILDREN$0
M01 · FY2000 · RR
TWO SAQUINAVIR TREATMENT REGIMENS IN HIV CHILDREN$0
M01 · FY2000 · RR
RITONAVIR THERAPY IN HIV-1 INFECTED INFANTS &CHILDREN$0
M01 · FY2000 · RR
RITONAVIR THERAPY IN HIV-1 INFECTED INFANTS &CHILDREN$0
M01 · FY2000 · RR
NEVIRAPINE PREVENTION OF HIV MATERNAL/ FETAL TRANSMISSIO$0
M01 · FY2000 · RR
NEVIRAPINE PREVENTION OF HIV MATERNAL/ FETAL TRANSMISSIO$0
M01 · FY2000 · RR
ACTG 366: RAD 1 FOUR DRUG ANTIRETROVIRAL COMBINATIONS BASED ON PRIOR$0
M01 · FY2000 · RR
PEDIATRIC LATE OUTCOMES$0
M01 · FY2000 · RR